DOP2023000263A - Compuestos indol sustituidos y métodos de uso de los mismos - Google Patents
Compuestos indol sustituidos y métodos de uso de los mismosInfo
- Publication number
- DOP2023000263A DOP2023000263A DO2023000263A DO2023000263A DOP2023000263A DO P2023000263 A DOP2023000263 A DO P2023000263A DO 2023000263 A DO2023000263 A DO 2023000263A DO 2023000263 A DO2023000263 A DO 2023000263A DO P2023000263 A DOP2023000263 A DO P2023000263A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- compounds
- methods
- substituted indol
- inhibitors
- complement
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163196339P | 2021-06-03 | 2021-06-03 | |
| US202163290019P | 2021-12-15 | 2021-12-15 | |
| US202263346120P | 2022-05-26 | 2022-05-26 | |
| PCT/US2022/032042 WO2022256586A2 (en) | 2021-06-03 | 2022-06-03 | Substituted indole compounds and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2023000263A true DOP2023000263A (es) | 2024-02-29 |
Family
ID=84323595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2023000263A DOP2023000263A (es) | 2021-06-03 | 2023-11-30 | Compuestos indol sustituidos y métodos de uso de los mismos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20240287034A1 (https=) |
| EP (1) | EP4346812A4 (https=) |
| JP (1) | JP2024521878A (https=) |
| KR (1) | KR20240017004A (https=) |
| CN (1) | CN120081822A (https=) |
| AU (1) | AU2022283903A1 (https=) |
| BR (1) | BR112023025235A2 (https=) |
| CA (1) | CA3222144A1 (https=) |
| CL (1) | CL2023003591A1 (https=) |
| CO (1) | CO2023016557A2 (https=) |
| CR (1) | CR20230564A (https=) |
| DO (1) | DOP2023000263A (https=) |
| EC (1) | ECSP23090260A (https=) |
| IL (1) | IL308835A (https=) |
| JO (1) | JOP20230315A1 (https=) |
| MX (1) | MX2023014274A (https=) |
| PE (1) | PE20250114A1 (https=) |
| PH (1) | PH12023553130A1 (https=) |
| WO (1) | WO2022256586A2 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230049115A (ko) * | 2020-08-07 | 2023-04-12 | 상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 | 보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도 |
| AU2021414253B2 (en) * | 2020-12-30 | 2024-05-16 | Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. | Series of piperidine-substituted benzoic acid compounds, and use thereof |
| EP4362933A4 (en) * | 2021-06-30 | 2025-06-04 | Apellis Pharmaceuticals, Inc. | COMPLEMENT INHIBITION |
| EP4389742A4 (en) * | 2021-08-18 | 2026-01-14 | Xizang Haisco Pharmaceutical Co Ltd | HETEROAROMATIC CYCLE DERIVATIVE CONTAINING BENZO NITROGEN AND ITS USE IN MEDICINE |
| TW202334121A (zh) * | 2021-10-27 | 2023-09-01 | 美商翰森生物有限責任公司 | 哌啶基吲哚衍生物、其製備方法及醫藥用途 |
| CA3247772A1 (en) * | 2022-01-24 | 2023-07-27 | Novartis Ag | Spirocyclic piperidinyl derivatives as complement factor B inhibitors and their uses |
| CN119301114A (zh) * | 2022-06-07 | 2025-01-10 | 正大天晴药业集团股份有限公司 | 双环取代的芳香羧酸类氘代化合物 |
| WO2023246677A1 (zh) * | 2022-06-20 | 2023-12-28 | 深圳信立泰药业股份有限公司 | 一种吲哚-苯基哌啶化合物及其制备方法与应用 |
| WO2023246870A1 (zh) * | 2022-06-23 | 2023-12-28 | 上海济煜医药科技有限公司 | 吲哚化合物的制备、应用及用途 |
| TW202423426A (zh) * | 2022-08-31 | 2024-06-16 | 美商奇努克醫療股份有限公司 | 經取代之吲哚化合物及其使用方法 |
| CA3266935A1 (en) * | 2022-09-10 | 2024-03-14 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Piperidine derivatives substituted at position 2, their preparation methods and medicinal uses |
| IL320661A (en) * | 2022-11-14 | 2025-07-01 | Novartis Pharma Ag | Solid forms of complement factor B inhibitors |
| TWI869080B (zh) * | 2022-11-29 | 2025-01-01 | 大陸商上海濟煜醫藥科技有限公司 | 苯並螺環吲哚化合物的製備及用途 |
| WO2024148274A1 (en) * | 2023-01-05 | 2024-07-11 | Apellis Pharmaceuticals, Inc. | Complement inhibition |
| WO2024149261A1 (zh) * | 2023-01-09 | 2024-07-18 | 南京正大天晴制药有限公司 | 补体因子b抑制剂 |
| EP4667465A1 (en) * | 2023-02-16 | 2025-12-24 | Haisco Pharmaceutical Group Co., Ltd. | Salt of benzo-nitrogen heteroaromatic ring derivative, crystalline form, and pharmaceutical use thereof |
| EP4670719A1 (en) * | 2023-02-22 | 2025-12-31 | Haisco Pharmaceutical Group Co., Ltd. | PHARMACEUTICAL COMPOSITION OF A HETEROAROMATIC BENZO-NITROGEN RING DERIVATIVE AND ITS USE IN MEDICINE |
| TW202506657A (zh) * | 2023-04-27 | 2025-02-16 | 大陸商上海翰森生物醫藥科技有限公司 | 一種哌啶基吲哚化合物的鹽及其製備方法 |
| IL325760A (en) | 2023-07-04 | 2026-03-01 | Sitala Bio Ltd | History of 2-(1H-indol-4-yl)methyl)-isoindoline as factor B inhibitors |
| CN121889385A (zh) | 2023-07-04 | 2026-04-17 | 希塔拉生物有限公司 | 作为因子b抑制剂的2-(1h-吲哚-4-基)甲基)2h-吲唑衍生物 |
| WO2025008517A1 (en) | 2023-07-06 | 2025-01-09 | Sitala Bio Ltd | Indole derivatives with factor b inhibitory activity |
| WO2025008516A2 (en) | 2023-07-06 | 2025-01-09 | Sitala Bio Ltd | Novel compounds |
| CN119371402A (zh) * | 2023-07-26 | 2025-01-28 | 上海美悦生物科技发展有限公司 | 螺环烯基类或氮杂烯基类化合物及其药物组合物、制备方法和用途 |
| CN119656165A (zh) * | 2023-09-20 | 2025-03-21 | 上海美悦生物科技发展有限公司 | 杂环化合物在制备预防和/或治疗肾脏疾病的药物中的用途 |
| WO2025119266A1 (zh) * | 2023-12-05 | 2025-06-12 | 西藏海思科制药有限公司 | 苯并氮杂芳环衍生物在治疗补体因子b介导的疾病中的用途 |
| WO2025172535A1 (en) | 2024-02-15 | 2025-08-21 | Sitala Bio Ltd | Indole and benzimidazole compounds as factor b inhibitors |
| WO2025256647A1 (zh) * | 2024-06-14 | 2025-12-18 | 润尔眼科药物（广州）有限公司 | 化合物及其医药用途 |
| WO2026008073A1 (zh) * | 2024-07-05 | 2026-01-08 | 南京正大天晴制药有限公司 | 补体因子b抑制剂的剂量组合物 |
| WO2026069246A1 (en) * | 2024-09-30 | 2026-04-02 | Novartis Ag | Complement factor b inhibitors and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA027113B1 (ru) * | 2012-05-04 | 2017-06-30 | Новартис Аг | Регуляторы пути комплемента и их применение |
| EP2867225B1 (en) * | 2012-06-28 | 2017-08-09 | Novartis AG | Pyrrolidine derivatives and their use as complement pathway modulators |
| JO3425B1 (ar) * | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| SG11201811491YA (en) * | 2016-06-27 | 2019-01-30 | Achillion Pharmaceuticals Inc | Quinazoline and indole compounds to treat medical disorders |
| KR20230049115A (ko) * | 2020-08-07 | 2023-04-12 | 상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 | 보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도 |
| TW202334121A (zh) * | 2021-10-27 | 2023-09-01 | 美商翰森生物有限責任公司 | 哌啶基吲哚衍生物、其製備方法及醫藥用途 |
-
2022
- 2022-06-03 CN CN202510248844.6A patent/CN120081822A/zh active Pending
- 2022-06-03 EP EP22816892.8A patent/EP4346812A4/en active Pending
- 2022-06-03 MX MX2023014274A patent/MX2023014274A/es unknown
- 2022-06-03 BR BR112023025235A patent/BR112023025235A2/pt unknown
- 2022-06-03 KR KR1020237045081A patent/KR20240017004A/ko active Pending
- 2022-06-03 CR CR20230564A patent/CR20230564A/es unknown
- 2022-06-03 JP JP2023574119A patent/JP2024521878A/ja active Pending
- 2022-06-03 WO PCT/US2022/032042 patent/WO2022256586A2/en not_active Ceased
- 2022-06-03 CA CA3222144A patent/CA3222144A1/en active Pending
- 2022-06-03 AU AU2022283903A patent/AU2022283903A1/en active Pending
- 2022-06-03 PH PH1/2023/553130A patent/PH12023553130A1/en unknown
- 2022-06-03 PE PE2023003178A patent/PE20250114A1/es unknown
- 2022-06-03 IL IL308835A patent/IL308835A/en unknown
- 2022-06-03 US US18/566,259 patent/US20240287034A1/en active Pending
-
2023
- 2023-11-30 EC ECSENADI202390260A patent/ECSP23090260A/es unknown
- 2023-11-30 DO DO2023000263A patent/DOP2023000263A/es unknown
- 2023-11-30 JO JOJO/P/2023/0315A patent/JOP20230315A1/ar unknown
- 2023-11-30 CL CL2023003591A patent/CL2023003591A1/es unknown
- 2023-11-30 CO CONC2023/0016557A patent/CO2023016557A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024521878A (ja) | 2024-06-04 |
| JOP20230315A1 (ar) | 2023-11-30 |
| EP4346812A2 (en) | 2024-04-10 |
| CA3222144A1 (en) | 2022-12-08 |
| WO2022256586A3 (en) | 2023-01-12 |
| PE20250114A1 (es) | 2025-01-16 |
| PH12023553130A1 (en) | 2024-03-11 |
| US20240287034A1 (en) | 2024-08-29 |
| BR112023025235A2 (pt) | 2024-02-27 |
| ECSP23090260A (es) | 2024-02-29 |
| IL308835A (en) | 2024-01-01 |
| MX2023014274A (es) | 2024-04-22 |
| KR20240017004A (ko) | 2024-02-06 |
| US20250289804A1 (en) | 2025-09-18 |
| CO2023016557A2 (es) | 2024-02-26 |
| EP4346812A4 (en) | 2025-04-09 |
| WO2022256586A2 (en) | 2022-12-08 |
| CR20230564A (es) | 2024-02-27 |
| CL2023003591A1 (es) | 2024-06-28 |
| CN120081822A (zh) | 2025-06-03 |
| AU2022283903A1 (en) | 2023-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP23090260A (es) | Compuestos indol sustituidos y métodos de uso de los mismos | |
| CO2022015638A2 (es) | Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso | |
| UY38403A (es) | Moduladores de la alfa-1 antitripsina | |
| CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
| CO2022008662A2 (es) | Degradadores de smarca y usos de los mismos | |
| NI201900077A (es) | Inhibidores selectivos de jak1 | |
| CR20180495A (es) | Deribados de indol sustituidos como inhibidores de replicación viral del dengue | |
| NI201800039A (es) | Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue | |
| NI201800040A (es) | Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue | |
| MX2024000349A (es) | Compuestos y usos de los mismos. | |
| UY36339A (es) | Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue | |
| PA8675701A1 (es) | Nuevos derivados del fluoreno, composiciones que los contienen y su utilización | |
| ECSP088676A (es) | Pirazolquinolonas como potentes inhibidores de parp | |
| CL2017001822A1 (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
| MX2018013164A (es) | Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa. | |
| CL2021001753A1 (es) | Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253). | |
| ECSP22085221A (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
| MX2021013386A (es) | Composiciones que comprenden indigo y/o un derivado de indigo y metodos de uso de las mismas. | |
| CL2020003380A1 (es) | Compuestos que aumentan la actividad del proteosoma. | |
| MX2016010524A (es) | Derivados de piridazina para uso en la prevencion o tratamiento de trastorno ataxico. | |
| CU20220025A7 (es) | Inihibidores del factor d del complemento para administración oral | |
| CL2025000581A1 (es) | Estructuras derivadas de tn3 específicas de cd40l; tratamiento, prevención del síndrome de sjögren | |
| CO2021014351A2 (es) | Derivados de quinolina y su uso para el tratamiento del cáncer | |
| MX2019001425A (es) | Composiciones y el uso de las mismas para el tratamiento o la prevención de la rosácea. |